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ABSTRACT
Background  Rheumatoid factors (RFs) and antibodies 
against cyclic citrullinated peptides (CCPs) of IgG, IgA and 
IgM isotype have been shown to precede disease onset 
by years.
Objective  To evaluate serological risk markers in ﬁ  rst-
degree relatives from multicase families in relation to 
genetic and environmental risk factors.
Methods  51 multicase families consisting of 163 
individuals with rheumatoid arthritis (RA) (mean±SD age, 
60±14 years; disease duration 21 years; 71.8% female) 
and with 157 ﬁ  rst-degree relatives unaffected by RA 
(54±17 years; 59.9% female) were recruited. Isotypes 
of antibodies against CCPs (IgG, IgA and IgM) and RFs 
(IgM and IgA) were determined using automated enzyme 
immunoassays. Cut-off levels were established using 
receiver operating characteristic curves based on values 
for 100 unrelated healthy controls.
Results  The concentrations and frequencies of all 
anti-CCP and RF isotypes were signiﬁ  cantly increased 
in ﬁ  rst-degree relatives and patients with RA compared 
with unrelated healthy controls. The relative distribution 
of IgA and IgM isotypes was higher than IgG in the 
relatives, whereas the IgG isotype dominated in patients 
with RA. The patients carried human leucocyte antigen-
shared epitope (HLA-SE) signiﬁ  cantly more often than the 
relatives (71.4% vs 53.9%, p=0.01), while the frequency 
of the PTPN22 T variant was similar. HLA-SE, combined 
with smoking, was signiﬁ  cantly related to all combinations 
of anti-CCP and RF isotypes in patients with RA. No such 
relationships were found for the ﬁ  rst-degree relatives.
Conclusions  All anti-CCP and RF isotypes analysed 
occurred more commonly in unaffected ﬁ  rst-degree 
relatives from multicase families than in controls, but with 
different isotype distribution from patients with RA.
INTRODUCTION
A genetic component of susceptibility to rheuma-
toid arthritis (RA) has long been suggested by data 
from twin and familial studies.1 2 Twin studies have 
estimated the inheritability of RA to be between 
50% and 60%,3 although the role of genetic fac-
tors has been questioned.4 Consistent associations 
implicate a role for genes located in the human 
leucocyte antigen (HLA) region in the risk of devel-
oping RA.5 Linkage studies support a role for the 
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HLA locus in genetic susceptibility to RA.6 A large 
number of genes have, in genome-wide asso-
ciation studies, been particularly associated with 
anti-citrullinated protein/peptide antibody (ACPA) 
positive patients with RA.7 8 Another robust asso-
ciation with RA is the R620W polymorphism of the 
PTPN22 locus.9 10 The association between the T 
variant of the PTPN22 gene and RA was more evi-
dent in patients seropositive for rheumatoid factors 
(RFs) and/or ACPAs.11–13 We have previously shown 
that a combination of antibodies against CCP with 
either HLA-shared epitope (SE) or the T variant of 
PTPN22 analysed before the onset of symptoms of 
disease strongly predicted future onset of RA with a 
high relative risk of developing RA.14 15
Smoking is one of the aetiological factors identi-
ﬁ  ed as a risk factor for RA.16 Data from a number 
of studies have suggested that a combination of 
HLA-SE alleles and exposure to tobacco interact in 
the development of ACPA-positive RA.17 18
In addition to the previously identiﬁ  ed IgG iso-
type, we have shown that ACPAs of either the IgA 
or IgM isotype predate the onset of RA by a num-
ber of years.19 20 All three isotypes were also signiﬁ  -
cantly increased after development of the disease. 
In addition, ACPAs have been shown to contrib-
ute to progression of arthritis in collagen-induced 
arthritis in mice, appearing 7 days after immunisa-
tion before clinical disease.21 Taken together, these 
results suggest a pathogenic role for ACPAs in the 
development of RA.
In a previous study of native North Americans 
with a high prevalence of severe RA, ACPAs of 
different isotypes were present with increased fre-
quency in the unaffected relatives of that cohort.22 
In another study of ﬁ  rst-degree relatives of patients 
with RA, the frequency of RFs and/or anti-CCP IgG 
increased to 16%.23
The aim of the present study was to analyse the 
isotypes of ACPAs and RFs in unaffected ﬁ  rst-degree 
relatives of patients with RA from multicase families 
from northern Sweden in relation to HLA-SE alleles 
and PTPN22 polymorphism and smoking habits.
MATERIALS AND METHODS
Familial clustering of RA was identiﬁ  ed using a ques-
tionnaire distributed to patients with RA attending 
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departments of rheumatology in the four northern-most coun-
ties of Sweden. All of the reported relatives from families who 
wished to participate were interviewed, by a second question-
naire, about symptoms and signs of joint disease. Affected rela-
tives were evaluated clinically by a rheumatologist and inspection 
of their medical records, and personal interviews were used to 
conﬁ  rm the diagnosis of RA (deﬁ  ned by the ACR 1987 criteria).24 
Sixty-one multicase families, with a total of 196 individuals with 
RA, were willing to participate. From 51 of these families, 157 
ﬁ  rst-degree relatives (59.9% female) who reported no symptoms 
of inﬂ  ammatory joint disease on a questionnaire evaluated by us 
were willing to donate blood samples. These 51 families included 
between two and 11 affected members with a total of 163 RA 
cases; 71.8% were female. Of the patients with RA, 62.6% had 
erosive disease and 21.5% had extra-articular manifestations.
IgG, IgA and IgM anti-CCP isotypes were determined in plasma 
using EliA anti-CCP assay on an ImmunoCAP 250 instrument 
(Phadia Diagnostic AB, Uppsala, Sweden), according to the man-
ufacturer’s instructions and as previously described.20 All samples 
above the upper limit were diluted further to obtain precise val-
ues. Within-study reference ranges were deﬁ  ned by receiver oper-
ating characteristic (ROC) curves, based on the patients with RA 
and healthy controls (n=100), whereby the optimal cut-off was 
deﬁ  ned as the antibody level yielding the highest sum of sensitiv-
ity and speciﬁ  city. The cut-offs determined were 3.3 AU/ml for 
IgG, 1.41 AU/ml for IgA and 59.9 AU/ml for IgM. Repeated analy-
sis of individual samples during the study period showed stable 
values. Cut-off values for RF IgA and IgM were deﬁ  ned by ROC 
curves to be 9.05 IU/ml and 4.8 IU/ml, respectively.
Genomic DNA was extracted using standard methods and 
analysed for a single-nucleotide polymorphism in PTPN22 
1858C/T (rs2476601) with a 5′-nuclease assay according to 
the manufacturer’s instructions (Applied Biosystems, Foster 
City, California, USA). The detection protocol used a 7900 HT 
Sequence Detection System (Applied Biosystems) in combina-
tion with SDS2.1 software (Applied Biosystems) to perform the 
genotyping. HLA-DRB1* analysis was performed using a DR 
low-resolution kit and DRB1*04 subtyping kit (Olerup SSP AB, 
Saltsjöbaden, Sweden). The HLA-SE was deﬁ  ned by DRB1*0401, 
0404 and 0408. Controls for genetic analyses were 193 people 
(age- and sex-matched for the patients with RA) identiﬁ  ed from 
the Medical Biobank, northern Sweden.
The regional ethics committee at the University Hospital, 
Umeå, Sweden approved the study, and all participants gave 
their written informed consent.
Statistical analysis
The χ2 test was used for categorical data, and non-paramet-
ric analysis for continuous data. Binary conditional logistic 
regression models were used to estimate predictive variables 
for the presence of RA in the families. Statistical analysis was 
performed using SPSS V.18.0 software. To allow distinction 
between ﬁ  rst-degree relatives and patients with RA, a multivari-
ate classiﬁ  cation algorithm termed the Random Forest method 
was used.25 Discrimination of the Random Forest models can 
be visualised graphically by using multidimensional scaling of 
the proximity matrix. The proximity is a relative measure of 
pair-wise relations derived from the set of decision trees in the 
Random Forest method. The prediction classiﬁ  cation  perfor-
mance of the Random Forest model can be translated to sensitiv-
ity and speciﬁ  city. Principal component scores were computed 
for the predictive variables to assess their multivariate relation-
ship. The principal component method combines the informa-
tion in several correlated variables and produces a few new 
independent scores based on linear combinations of the risk fac-
tors. It has the advantage of explaining most of the variability in 
the original data.
RESULTS
The mean±SD age of the family members with RA was sig-
niﬁ  cantly higher than that of their relatives (60±14 years and 
54±17 years, respectively). They had a mean disease duration of 
21±15.6 years. The frequency of current or past smoking hab-
its was higher among the patients with RA (57.9% vs 46.9%, 
respectively), but this difference was not signiﬁ  cant. The fre-
quency of HLA-DRB1*0401/0404/0408 was 53.9% in ﬁ  rst-de-
gree relatives and 71.4% in patients with RA (p<0.01); both of 
these frequencies were signiﬁ  cantly increased compared with 
that of the control population (35.8%). Of the patients with RA, 
12.8% had double SE alleles compared with 1.3% of the rela-
tives (p<0.001) and 5.6% of the controls. The PTPN22 T variant 
was signiﬁ  cantly more prevalent in both ﬁ  rst-degree relatives 
(46.8%) and patients with RA (47.8%) compared with controls 
(19.5%).
The concentrations of ACPA isotypes IgG, IgM and IgA and 
RF isotypes IgM and IgA were signiﬁ  cantly increased in ﬁ  rst-
degree relatives compared with controls, and were further 
increased in patients with RA (table 1). These concentrations 
were also signiﬁ  cantly increased in patients with RA compared 
with their ﬁ  rst-degree relatives (p<0.001 for all isotypes). High 
concentrations (deﬁ  ned as three times above cut-off) of ACPA 
isotypes IgM, IgA and IgG were found in 5.1%, 4.5% and 5.7%, 
respectively, of ﬁ   rst-degree relatives compared with 21.5%, 
42.9% and 81.0% of patients with RA (online supplementary 
ﬁ  gure S1A–C).
In the ﬁ   rst-degree relatives, the frequency of the different 
ACPA isotypes was 21.7% for IgG, 26.8% for IgA and 22.3% 
for IgM, with speciﬁ  cities of 98%, 99% and 94%, respectively 
Table 1  Concentration of the different isotypes of CCP2 antibodies (AU/ml) and RFs (IU/ml) in healthy 
controls, patients with RA and ﬁ  rst-degree relatives
  IgG-CCP2 IgA-CCP2 IgM-CCP2 IgM-RF IgA-RF
Controls (n=100) 1.5 0.6 18.5 0.8 3.4
 IQR (1.0–2.2) (0.4–0.7) (9.6–30.9)  (0.6–1.2) (2.7–4.7)
First-degree relatives (n=157) 2.2*** 1.0*** 27.9*** 1.3*** 4.7***
 IQR (1.4–3.1) (0.7–1.5) (13.7–53.3) (0.9–2.4) (3.4–8.0)
RA patients (n=163) 235.0*** 2.8*** 51.7*** 29.9*** 24.6***
 IQR (27.0–569.0) (1.3–13.0) (22.5–140.0) (4.6–134.3) (8.8–60.3)
p Value† <0.001 <0.001 <0.001 <0.001 <0.001
Values are median (Q1–Q3).
***p<0.001, refers to post-hoc comparisons between ﬁ  rst-degree relatives or RA patients versus controls.
†Kruskal–Wallis test for three independent samples.
CCP, cyclic citrullinated peptide; RA, rheumatoid arthritis; RF, rheumatoid factor.
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presence of IgG ACPAs than for presence of IgM-RF, but stratiﬁ  -
cation for either antibody did not give consistent results for an 
association with ACPA irrespective of seropositivity for IgM-RF 
(data not shown). Principal component analysis including the 
isotypes of ACPA and RF, HLA-SE and T variant of PTPN22, 
smoking habits, age and sex showed that IgG-ACPA isotype 
and IgM-RF correlated highly, and these two variables alone 
can describe 98% of the information from all factors together.
Random Forest modelling including the concentrations of 
ACPA and RF isotypes, genes, smoking habits and also age and 
sex gave a sensitivity of 90.7% for having RA, with a speciﬁ  city 
of 81.8% for discriminating between ﬁ  rst-degree relatives and 
patients with RA. A plot illustrating the relationships between 
the patients and the relatives according to the discriminating vari-
ables (ACPA, RF isotypes, genes, smoking habits, age and sex) is 
presented in ﬁ  gure 2. Thus observations that are close together 
are more closely related than those that are further apart. The 
ﬁ  rst dimension of the multidimensional scaling variable shows 
the best discrimination according to the proximities.
An individual summation of these eight factors (ie, ACPA and 
RF isotypes, HLA-SE, PTPN22 T variant and smoking habits) 
as risk markers showed that patients with RA had a median 
(Q1–Q3) number of 6 (4–7) of these factors, whereas their rela-
tives had 2 (1–3) (Mann–Whitney U test, p<0.001).
(table 2). All of the ACPA isotypes were signiﬁ  cantly increased 
compared with healthy controls. The frequency of the IgM-RF 
isotype was increased signiﬁ  cantly to 14.0%, and that of IgA-RF 
to 22.3% at speciﬁ  cities of 95% and 94%, respectively. The sen-
sitivity for all ACPA and RF isotypes was highly signiﬁ  cant in 
the patients with RA compared with controls (table 2).
The numbers of ACPA isotypes identiﬁ  ed in the ﬁ  rst-degree 
relatives, patients with RA and controls were signiﬁ  cantly dif-
ferent (Kruskal–Wallis, p<0.0001, between the three groups; 
Mann–Whitney, p<0.001 for both relatives vs RA patients and vs 
controls; data not shown). Sixty-ﬁ  ve (38.7%) of the patients with 
RA were positive for all three isotypes, as were six (7.1%) of the 
symptom-free ﬁ  rst-degree relatives, while 49 (31.2%) of the latter 
group showed the presence of one isotype. The distribution of 
each isotype and their combinations presented in ﬁ  gure 1 show 
that the number of isolated IgA- and IgM-positive ACPA isotypes 
in relation to isolated IgG isotype were signiﬁ  cantly higher in 
ﬁ  rst-degree relatives than in patients with RA (p<0.0001 for each 
type). There were no signiﬁ  cant differences in the distribution of 
RFs in ﬁ  rst-degree relatives compared with RA patients (ﬁ  gure 1).
Stratiﬁ  cation of the patients with RA and their ﬁ  rst-degree rel-
atives for ACPA and RF status showed, in simple logistic regres-
sion analyses, that there was a signiﬁ  cant relationship between 
HLA-SE and IgG isotype of ACPAs in the patients with RA 
(table 3). There were signiﬁ  cant relationships between smok-
ing and the IgM isotype and the combination of all three ACPA 
isotypes, and with IgA-RF and a combination of both RFs mea-
sured. However, the combination of HLA-SE and current or past 
smoking habits was related to all three ACPA isotypes both sep-
arately and in combination, and also in combination with RFs, 
while none of these associations were found in the ﬁ  rst-degree 
relatives (table 3). In fact, all patients with RA with SE and being 
current or past smokers were positive for the ACPA IgG isotype. 
To permit calculation, one of these patients was recorded as 
being IgG-ACPA negative. There were no relationships between 
any of the isotypes and PTPN22 polymorphism in patients with 
RA or their ﬁ  rst-degree relatives (data not shown).
The ACPA isotypes (with the highest OR for the IgG isotype 
followed by IgA), RF isotypes, HLA-SE and age all differenti-
ated, in simple conditional logistic regression analyses, patients 
with RA from ﬁ  rst-degree relatives (p<0.0001–0.05), while ever-
smoking, T variant of PTPN22 and sex did not (table 4). In a 
multiple conditional backwards regression analysis including all 
of the signiﬁ  cant variables from the simple regression analyses, 
IgG ACPAs (OR 3.46, 95% CI 1.94 to 6.18, p<0.0001) and IgM 
RF (OR 1.71, 95% CI 1.06 to 2.76, p<0.05) were the remaining 
signiﬁ  cant variables that distinguished patients with RA from 
ﬁ  rst-degree relatives within the families. The OR was higher for 
Table 2  Frequency and diagnostic sensitivity and speciﬁ  city of ACPA 
isotypes and RF isotypes in ﬁ  rst-degree relatives and RA patients from 
multicase families
Frequency Sensitivity Speciﬁ  city
  First-degree relatives, 
n (%)
Patients with RA, 
n (%) %
IgG anti-CCP 34 (21.7)*** 140 (85.9)*** 98
IgA anti-CCP 42 (26.8)*** 118 (72.4)*** 99
IgM anti-CCP 35 (22.3)***   74 (45.4)*** 94
IgM-RF 22 (14.0)* 121 (74.2)*** 95
IgA-RF 35 (22.3)*** 123 (75.5)*** 94
*p< 0.05, ***p<0.001, patients with RA and ﬁ  rst-degree relatives versus healthy 
controls.
ACPA, anti-citrullinated protein/peptide antibody; CCP, cyclic citrullinated peptide; 
RA, rheumatoid arthritis; RF, rheumatoid factor.
Figure 1  (A) Distribution of each anti-citrullinated protein/peptide 
antibody (ACPA) isotype and combinations in controls, ﬁ  rst-degree 
relatives and patients with rheumatoid arthritis (RA). The number of 
isolated IgA- and IgM-positive ACPA isotypes in relation to isolated IgG 
isotype was signiﬁ  cantly higher in ﬁ  rst-degree relatives than in patients 
with RA (p<0.0001 for each type). (B) Distribution of each rheumatoid 
factor isotype in controls, ﬁ  rst-degree relatives and patients with RA. 
No ab, no antibody.
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our ﬁ  ndings on RFs are consistent with the results presented 
by MacGregor et al in 1995,3 who found in twin studies that 
seropositivity for RF had a genetic contribution independent of 
HLA-DR. Also, in another large study of 1058 ﬁ  rst-degree rela-
tives, no signiﬁ  cant association between autoantibodies and the 
presence of HLA-SE or PTPN22 polymorphism was found.23
The lack of association found in this study could also be a 
result of too few individuals being antibody and HLA-SE posi-
tive compared with RA patients, making it more difﬁ  cult  to 
show relationships. In a number of recent studies, genetic fac-
tors have been identiﬁ  ed in the HLA region that protect against 
the development of RA.27 In particular, the presence of HLA-
DRB1*1301/1302 has been identiﬁ  ed as being protective.27 In the 
present study, we were unable to analyse for HLA-DRB1 alleles 
associated with protective effects on the development of ACPAs 
or RA, although this could be a tentative explanation of why the 
relatives with SE and/or PTPN22 T allele and ACPAs, with pre-
dominantly immature isotypes, have not developed RA.
DISCUSSION
In this study of patients with RA and their ﬁ  rst-degree asymp-
tomatic relatives from multicase families, we found signiﬁ  cantly 
increased concentrations of both ACPA and RF isotypes com-
pared with healthy controls. The frequencies of these isotypes 
were also signiﬁ  cantly increased, based on ROC curves con-
structed using data from patients with RA and healthy controls. 
Our analyses detected a surprisingly high frequency of ACPA 
isotypes in symptom-free ﬁ  rst-degree relatives. The prevalence 
of the IgG isotype of ACPA in our study was slightly higher than 
in studies from the USA and Canada despite a number of the 
ﬁ  rst-degree relatives in the former study having swollen and/or 
tender joints.22 23 The frequencies of RF isotypes were similar 
to those in the Canadian study (15.4% for IgM-RF and 21.6% 
for IgA-RF), but slightly higher than in the US study (4.7% and 
3.8%, respectively).22 23 As we had also analysed the two genes 
most commonly related to RA and collected data on smoking 
habits in most of the subjects, we were able to compare these 
asymptomatic relatives with their family members who had 
RA with respect to these factors. We were unable to relate the 
presence of ACPA or RF isotypes in the ﬁ  rst-degree relatives to 
either of the two gene polymorphisms, to smoking habits or to 
demographic data such as age or sex. We could not conﬁ  rm that 
HLA-SE alleles were a risk factor for development of ACPAs in 
the ﬁ  rst-degree relatives, which was the case for the IgG iso-
type in the patients with RA in this study and as has been sug-
gested by others.26 All patients with RA who were SE positive 
and had ever smoked had ACPAs of the IgG isotype. However, 
Table 4  Results of simple conditional logistic regression analyses of 
the different isotypes of anti-CCP2 antibodies, RFs, HLA-SE, PTPN22 
1858T and smoking with ﬁ  rst-degree relatives and patients with RA as 
dependent variable
Factor OR (95%CI)  p Value
IgG-CCP 5.80 (3.61 to 9.30) <0.0001
IgA-CCP 2.47 (1.74 to 3.51) <0.0001
IgM-CCP 1.46 (1.07 to 1.99) <0.05
IgA-RF 3.12 (2.16 to 4.50) <0.0001
IgM-RF 3.64 (2.50 to 5.29) <0.0001
HLA-SE 1.56 (1.00 to 2.42) <0.05
PTPN22 1858T  1.23 (0.83 to 1.82) NS
Smoking 1.28 (0.92 to 1.78) NS
Age 1.02 (1.01 to 1.03) <0.01
Sex 1.28(0.92 to 1.79) NS
CCP, cyclic citrullinated peptide; RA, rheumatoid arthritis; RF, rheumatoid factor; 
HLA-SE, human leucocyte antigen shared epitope.
Table 3  Risk of antibody-positivity predicted by HLA-SE, smoking and HLA-SE+smoking in patients with RA and their ﬁ  rst-degree relatives
Patients with RA First-degree relatives
Antibody SE Smoking ever SE+smoking ever SE Smoking ever SE+smoking ever
IgG-ACPA 4.71 (1.84 to 12.05) 2.17 (0.90 to 5.23) 19.33 (2.54 to 147.21)* 0.55 (0.25 to 1.21) 1.37 (0.63 to 2.95) 0.71 (0.28 to 1.81)
IgA-ACPA 2.03 (0.96 to 4.30) 1.89(0.94 to 3.79) 2.81 (1.27 to 6.24) 0.47 (0.22 to 0.97) 1.36 (0.65 to 2.85) 0.76 (0.31 to 1.86)
IgM-ACPA 1.30 (0.64 to 2.63) 2.33(1.21 to 4.48) 2.17 (1.07 to 4.00) 0.76 (0.35 to 1.64) 0.79 (0.36 to 1.73) 0.79 (0.31 to 2.02)
IgG+IgA+IgM-ACPA 1.78 (0.84 to 3.77) 2.39 (1.21 to 4.71) 2.98 (1.51 to 5.89)  0.20 (0.02 to 1.87) 1.14 (0.22 to 5.82) 0.71 (0.08 to 6.48)
IgM-RF 1.85 (0.86 to 4.0) 1.76 (0.87 to 3.58) 2.45 (1.10 to 5.46) 0.75 (0.30 to 1.88) 0.75 (0.30 to 1.88) 0.43 (0.12 to 1.54)
IgA-RF 1.36 (0.62 to 2.96) 2.31 (1.11 to 4.78) 2.23 (0.99 to 4.98) 1.11 (0.51 to 2.38) 1.61 (0.73 to 3.55) 1.21 (0.50 to 2.94)
IgM+IgA-RF 1.47 (0.71 to 3.05) 2.16 (1.11 to 4.23) 2.53 (1.21 to 5.28) 0.58 (0.18 to 1.93) 0.97 (0.31 to 3.03) 0.24 (0.03 to 1.91)
Values are OR (95% CI).
*All ever-smoking patients with RA with SE had IgG isotype antibodies. To permit this calculation, one of these patients was recorded as IgG negative.
ACPA, anti-citrullinated protein/peptide antibody; HLA, human leucocyte antigen; RA, rheumatoid arthritis; SE, shared epitope.
Figure 2  Visualisation of multidimensional scaling demonstrating 
clustering of ﬁ  rst-degree relatives and patients with rheumatoid arthritis 
according to a set of predictive variables in a Random Forest model. 
The two axes represent the dominant clustering directions between the 
groups scaled as proximities. Dim, dimension.
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The sensitivity of all ACPA isotypes was higher for patients 
with RA in this study than in our previous study of patients with 
early RA, when we used the same laboratory procedure and 
ROC curve calculations to determine cut-off values, in which 
the sensitivity was 71.7% for IgG, 43.3% for IgA and 32.8% 
for IgM.20 In that study the sensitivity for the IgG isotype was 
higher (33.8%) among individuals (referred to as prepatients) 
who subsequently developed RA compared with the ﬁ  rst-degree 
relatives of patients in the present study. The frequency for the 
IgM isotype was higher among ﬁ  rst-degree relatives than among 
prepatients (22.4% vs 11.8%, χ2=3.69, p=0.058). For the IgA iso-
type, the frequencies were similar (26.9% vs 23.9%) compared 
with prepatients. The number of people (n=156) providing 
samples for the present study was double that of the previous 
study based on samples predating disease onset (n=71). The 
median predating time for the prepatients was 2.5 years before 
they developed symptoms of RA disease, while in the present 
study, we do not yet know if the ﬁ  rst-degree relatives will ever 
develop RA. One argument against the later appearance of RA in 
at least some of the autoantibody-positive ﬁ  rst-degree relatives 
is the age distribution. The mean age of the patients with RA 
was 60 years compared with 54 years for the ﬁ  rst-degree rela-
tives. However, as the mean disease duration was 21 years, the 
patients with RA had a mean age at diagnosis of 39 years—that 
is, 15 years younger than their relatives included in the study.
An interesting observation among the ﬁ  rst-degree relatives 
was the relative increase in IgA and IgM antibodies compared 
with ACPAs of the IgG isotype. This antibody pattern differed 
distinctly from that in the patients with RA. One can speculate 
whether this is a predisease pattern that will change when the 
disease develops or represents an abortive form of autoimmu-
nity that will never lead to a switch to the IgG isotype tradi-
tionally associated with RA. The fact that we found a higher 
percentage of IgM anti-CCP positive subjects among the ﬁ  rst-
degree relatives in the present study compared with among pre-
patients in our earlier study20 argues for the latter possibility, 
as does the fact that our group of symptom-free relatives were 
15 years older at inclusion than their relatives with RA when 
they were diagnosed.
In conclusion, in this study on multicase families with RA, 
ﬁ  rst-degree asymptomatic relatives have increased concentra-
tions of all ACPA and RF isotypes without any signiﬁ  cant rela-
tionship of these antibodies to HLA-SE, PTPN22 polymorphism 
or smoking habits. The presence of protective factors may pre-
vent these relatives from developing the disease, but a later dis-
ease onset should also be considered a possibility, which could 
be investigated with appropriate follow-up protocols.
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